{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:06:15Z","timestamp":1791525975568,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.eururo.2019.07.010","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:23:10Z","timestamp":1565655790000},"page":"767-779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment"],"prefix":"10.1016","volume":"76","author":[{"given":"Christian","family":"Gratzke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Chapple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dudley","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Staskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stoelzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob van","family":"Maanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2019.07.010_bib0005","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/nau.22609","article-title":"Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013","volume":"33","author":"Drake","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2019.07.010_bib0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","article-title":"The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society","volume":"61","author":"Abrams","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2019.07.010_bib0015","first-page":"71","article-title":"Review of the epidemiology of overactive bladder","volume":"8","author":"Eapen","year":"2016","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.eururo.2019.07.010_bib0020","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","article-title":"Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction","volume":"108","author":"Irwin","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2019.07.010_bib0025","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.eururo.2017.12.031","article-title":"EAU guidelines on assessment and nonsurgical management of urinary incontinence","volume":"73","author":"Nambiar","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.07.010_bib0030","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-018-0924-4","article-title":"Mirabegron: a review in overactive bladder syndrome","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.eururo.2019.07.010_bib0035","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/iju.13758","article-title":"Anticholinergic burden in the Japanese elderly population: use of antimuscarinic medications for overactive bladder patients","volume":"25","author":"Yoshida","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2019.07.010_bib0040","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment","volume":"193","author":"Gormley","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.07.010_bib0045","doi-asserted-by":"crossref","first-page":"E142","DOI":"10.5489\/cuaj.4586","article-title":"CUA guideline on adult overactive bladder","volume":"11","author":"Corcos","year":"2017","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.eururo.2019.07.010_bib0050","first-page":"43","article-title":"Effectiveness of combined high-dosed trospium and solifenacin depending on severity of OAB symptoms in elderly men and women under cyclic therapy","volume":"67","author":"Kosilov","year":"2014","journal-title":"Cent Eur J Urol"},{"key":"10.1016\/j.eururo.2019.07.010_bib0055","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000363658","article-title":"Comparative effectiveness of combined low- and standard-dose trospium and solifenacin for moderate overactive bladder symptoms in elderly men and women","volume":"93","author":"Kosilov","year":"2014","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2019.07.010_bib0060","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/2051415815600970","article-title":"Influence of different doses of trospium and solifenacin on manageability of OAB symptoms with different severity in elderly men and women","volume":"9","author":"Kosilov","year":"2016","journal-title":"J Clin Urol"},{"key":"10.1016\/j.eururo.2019.07.010_bib0065","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1186\/s13104-015-1604-z","article-title":"Rapid Evidence Assessment of the Literature (REAL((c))): streamlining the systematic review process and creating utility for evidence-based health care","volume":"8","author":"Crawford","year":"2015","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.eururo.2019.07.010_bib0070","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jclinepi.2012.01.006","article-title":"GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.eururo.2019.07.010_bib0075","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00345-016-1908-1","volume":"35","author":"Abrams","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2019.07.010_bib0080","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2014.02.012","article-title":"Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (SYMPHONY)","volume":"67","author":"Abrams","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.07.010_bib0085","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.eururo.2016.02.030","article-title":"Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3b study (BESIDE)","volume":"70","author":"Drake","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.07.010_bib0090","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.12944","article-title":"Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)","volume":"71","author":"Drake","year":"2017","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.eururo.2019.07.010_bib0095","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.euf.2017.08.008","article-title":"Treating overactive bladder in older patients with a combination of mirabegron and solifenacin: a prespecified analysis from the BESIDE study","volume":"3","author":"Gibson","year":"2017","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2019.07.010_bib0100","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.eururo.2018.05.005","article-title":"Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II)","volume":"74","author":"Gratzke","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.07.010_bib0105","first-page":"677","article-title":"Assessing preference-based outcome measures for overactive bladder: an evaluation of patient-reported outcome data from the BESIDE clinical trial","volume":"10","author":"Herdman","year":"2017","journal-title":"Patient"},{"key":"10.1016\/j.eururo.2019.07.010_bib0110","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/bju.13882","article-title":"Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)","volume":"120","author":"Herschorn","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2019.07.010_bib0115","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5213\/inj.2013.17.4.191","article-title":"Maintenance of the therapeutic effect of two high-dosage antimuscarinics in the management of overactive bladder in elderly women","volume":"17","author":"Kosilov","year":"2013","journal-title":"Int Neurourol J"},{"key":"10.1016\/j.eururo.2019.07.010_bib0120","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.archger.2015.06.006","article-title":"A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron","volume":"61","author":"Kosilov","year":"2015","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.eururo.2019.07.010_bib0125","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/1756287214544896","article-title":"Randomized controlled trial of cyclic and continuous therapy with trospium and solifenacin combination for severe overactive bladder in elderly patients with regard to patient compliance","volume":"6","author":"Kosilov","year":"2014","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.eururo.2019.07.010_bib0130","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/nau.23315","article-title":"Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients","volume":"37","author":"Robinson","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2019.07.010_bib0135","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4111\/icu.2017.58.4.261","article-title":"Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy","volume":"58","author":"Shin","year":"2017","journal-title":"Invest Clin Urol"},{"key":"10.1016\/j.eururo.2019.07.010_bib0140","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/MBP.0000000000000320","article-title":"A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial","volume":"23","author":"Weber","year":"2018","journal-title":"Blood Press Monit"},{"key":"10.1016\/j.eururo.2019.07.010_bib0145","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.1107","article-title":"Cardiovascular safety of the \u03b23-Adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial","author":"White","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.eururo.2019.07.010_bib0150","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/bju.13068","article-title":"Safety and efficacy of mirabegron as \u2018add-on\u2019 therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study)","volume":"116","author":"Yamaguchi","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2019.07.010_bib0155","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.juro.2016.03.174","article-title":"Mirabegron as add-on treatment to solifenacin in patients with incontinent overactive bladder and an inadequate response to solifenacin monotherapy","volume":"196","author":"MacDiarmid","year":"2016","journal-title":"Journal of Urology"},{"key":"10.1016\/j.eururo.2019.07.010_bib0160","doi-asserted-by":"crossref","first-page":"e607","DOI":"10.1016\/j.juro.2017.03.073","article-title":"Long-term combination treatment with solifenacin and mirabegron is effective and well tolerated in patients with overactive bladder","volume":"197","author":"Gratzke","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.07.010_bib0165","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.juro.2006.03.088","article-title":"Determining the importance of change in the overactive bladder questionnaire","volume":"176","author":"Coyne","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.07.010_bib0170","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/iju.13868","article-title":"Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: a multicenter, randomized study in Japan (MILAI II study)","volume":"26","author":"Yamaguchi","year":"2019","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2019.07.010_bib0175","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000000309","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment","author":"Lightner","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2019.07.010_bib0180","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.eururo.2018.10.006","article-title":"Vibegron (RVT-901\/MK-4618\/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial","volume":"75","author":"Mitcheson","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2019.07.010_bib0185","series-title":"The production of quick scoping reviews and rapid evidence assessments. A how to guide","author":"Collins","year":"2015"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283819305342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283819305342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:06:19Z","timestamp":1759583179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283819305342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0302283819305342"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2019.07.010","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2019.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}